VolitionRx Limited (NYSE American: VNRX) has announced the release of a clinical study highlighting the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted in collaboration with researchers and clinicians at France's Hospices Civils de Lyon, the real-world study examined the assay's H3K27Me3-nucleosome biomarker and found that its levels were significantly associated with cancer stage, overall survival, and progression-free survival. The paper is currently under peer review.
According to the company, a prognostic model that incorporated the biomarker along with clinical factors successfully stratified patients into low- and high-risk mortality groups. These findings suggest that the Nu.Q Cancer Assay could play a role in personalizing treatment selection and improving clinical decision-making for lung cancer patients. VolitionRx noted that clinical certification of the test at Hospices Civils de Lyon has been completed, and the company is preparing a reimbursement submission in France under the RIHN framework.
The company is also pursuing commercialization opportunities with hospital networks and potential licensing partners internationally. Reimbursement is considered a key milestone toward routine clinical use in France. For more details, the full press release is available at https://ibn.fm/dhJZ6.
VolitionRx is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, the company develops and commercializes simple, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. Further information can be found on the company's website at https://volition.com/.
